THE CLINICAL IMPORTANCE OF DRUG-INTERACTIONS WITH ANTIULCER THERAPY

被引:32
作者
REYNOLDS, JC [1 ]
机构
[1] UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261
关键词
Drug interactions; H[!sub]2[!/sub]-receptor antagonists; Omeprazole; Sucralfate;
D O I
10.1097/00004836-199000000-00010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The overall safety of a given drug is determined by its toxicity, side effects, and drug-drug interactions. Thus, a clarification of the mechanisms, importance, and clinical implications of any drug-drug interaction with antiulcer therapy is critical to the use of antiulcer medications. Drug-drug interactions may occur as a result of changes in absorption, metabolism, distribution, or excretion. Fortunately, drug distribution or protein binding is unchanged by antiulcer therapy. Antiulcer drugs may affect absorption by several mechanisms. Ionized medications may bind to the divalent cations of antacids and sucralfate to result in poorly absorbed complexes. Reduced gastric acid may decrease the absorption of medications that are weak bases while enhancing the absorption of weak acids. Drug absorption may be impaired by delayed gastric emptying. Several H2-receptor antagonists, including cimetidine and to a lesser extent ranitidine, and the proton pump inhibitor, omeprazole, may reduce the hepatic degradation of drugs metabolized by the cytochrome P450 system. The degree to which such agents alter drug metabolism is determined by the patient's age, genetics, duration of therapy, degree of cytochrome P450 binding, and the regimen. Because the clinical importance of this interaction cannot always be predicted, caution is recommended whenever drugs metabolized by this system are used concurrently. Development of an understanding of the ways in which drug metabolism interactions occur may lead to more effective and safe use of these medications. © 1990 Raven Press, Ltd., New York.
引用
收藏
页码:S54 / S63
页数:10
相关论文
共 69 条
[1]   RANITIDINE DOES NOT IMPAIR OXIDATIVE OR CONJUGATIVE METABOLISM - NONINTERACTION WITH ANTIPYRINE, DIAZEPAM, AND LORAZEPAM [J].
ABERNETHY, DR ;
GREENBLATT, DJ ;
ESHELMAN, FN ;
SHADER, RI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (02) :188-192
[2]   DOSE-DEPENDENT EFFECT OF CIMETIDINE ON PHENYTOIN KINETICS [J].
BARTLE, WR ;
WALKER, SE ;
SHAPERO, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (05) :649-655
[3]   EFFECT OF RANITIDINE ON COBALAMIN ABSORPTION [J].
BELAICHE, J ;
CATTAN, D ;
ZITTOUN, J ;
MARQUET, J ;
YVART, J .
DIGESTIVE DISEASES AND SCIENCES, 1983, 28 (07) :667-668
[4]   EFFECTS OF CIMETIDINE AND RANITIDINE ON HEPATIC DRUG-METABOLISM [J].
BREEN, KJ ;
BURY, R ;
DESMOND, PV ;
MASHFORD, ML ;
MORPHETT, B ;
WESTWOOD, B ;
SHAW, RG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (03) :297-300
[5]  
CABALLERIA J, 1989, Gastroenterology, V96, pA581
[6]   EFFECTS OF CIMETIDINE ON GASTRIC ALCOHOL-DEHYDROGENASE ACTIVITY AND BLOOD ETHANOL LEVELS [J].
CABALLERIA, J ;
BARAONA, E ;
RODAMILANS, M ;
LIEBER, CS .
GASTROENTEROLOGY, 1989, 96 (02) :388-392
[7]   CIMETIDINE DECREASES THEOPHYLLINE CLEARANCE [J].
CAMPBELL, MA ;
PLACHETKA, JR ;
JACKSON, JE ;
MOON, JF ;
FINLEY, PR .
ANNALS OF INTERNAL MEDICINE, 1981, 95 (01) :68-69
[8]   FAMOTIDINE - PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND A PRELIMINARY REVIEW OF ITS THERAPEUTIC USE IN PEPTIC-ULCER DISEASE AND ZOLLINGER-ELLISON SYNDROME [J].
CAMPOLIRICHARDS, DM ;
CLISSOLD, SP .
DRUGS, 1986, 32 (03) :197-221
[9]   HISTAMINE H1-RECEPTOR AND H2-RECEPTOR IN THE GASTROINTESTINAL CIRCULATION [J].
CHARBON, GA ;
BROUWERS, HAA ;
SALA, A .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1980, 312 (02) :123-129
[10]  
CORINALDESI R, 1984, INT J CLIN PHARM TH, V22, P498